title: [Organ-preserving interventions in combined therapy of children and adolescents with osteosarcoma].
abstract: An analyzed cohort consists of 50 pediatric patients with osteosarcoma receiving combined therapy in N. N. Petrov Research Institute for Oncology (1999-2010). Thirty nine of them had localized disease, 11 patients had distant metastases. The treatment scheme included neoadjuvant therapy with cisplatin and doxorubicin, surgical treatment and adjuvant therapy depended on initial response and could include cisplatin, doxorubicin, high-dose methotrexate, ifosfamide, etoposide. Four-year overall and relapse-free survival in children with localized disease was 74.3% and 69.2% accordingly. In 62% of patients were performed organ-preserving surgical interventions, in 22 patients was performed endoprosthetics, in 4 patients the defect was replaced by a bone autograft on a vascular bundle. The effectiveness of initial treatment and secondary endoprosthetics were analyzed. Six patients with lung metastases received normotermic lung chemoperfusion, 4 of them are alive and disease-free for 8 to 24 months.
authors: Iu A
authors: IuA
authors: Punanov
authors: G I
authors: GI
authors: Gafton
authors: Iu V
authors: IuV
authors: Gudz'
authors: V V
authors: VV
authors: Nabokov
authors: T V
authors: TV
authors: Ivanova
authors: S A
authors: SA
authors: Safonova
authors: E V
authors: EV
authors: Levchenko
authors: D D
authors: DD
authors: Kupatadze
authors: V I
authors: VI
authors: Novik
authors: Iu R
authors: IuR
authors: Lazareva
authors: P I
authors: PI
authors: Krzhivitskiĭ
authors: V G
authors: VG
authors: Petrov
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D016025:Bone Transplantation; D010478:Chemotherapy, Cancer, Regional Perfusion; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage; D015331:Cohort Studies; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D020360:Neoadjuvant Therapy / Q000379:methods*; D019637:Orthopedic Procedures / Q000379:methods*; D012516:Osteosarcoma / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin; D007069:Ifosfamide; D008727:Methotrexate